NASDAQ · CTCX
Healthcare · Biotechnology
$0.20
Up+$0.00 (+1.39%)
Updated Aug 23, 2026, 11:50 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CTCX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning CTCX.
CTCX research
Company profile and research snapshot.
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
defenseworld.net · Nov 5, 2025
Valuation and Earnings This table compares Carmell and its competitors revenue, earnings per share (EPS) and valuation. Gross Revenue Net Income Price/Earnings Ratio Carmell $32,839.00 -$15.44 million -1.17 Carmell Competitors $170.32 million -$17.87 million -11.50 Carmell's competitors have higher revenue, but lower earnings than Carmell. Carmell is trading at a higher price-to-earnings ratio than its
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CTCX.
No results
No recent SID articles mention CTCX.
